There is no big difference between the price of Forxiga and DPP-4 inhibitors

Published: 2014-05-16 15:31:36

Updated: 2014-05-16 15:31:36

On May 14, according to the related industry, AstraZeneca got healthcare insurance benefit approval of SGLT-2 inhibitor 'Forxiga (dapagliflozin)' from Health Insurance Review & Assessment, drug insurance benefit Assessment Board.

The upper price limit of Forxiga was already determined. In Last Mar, AstraZeneca launched Forxiga with the price of 999 won which is uncovered by health insurance. T...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.